Atrium Therapeutics, Inc. (RNA)
10.36
-0.15
(-1.43%)
USD |
NASDAQ |
Sep 10, 16:00
10.36
0.00 (0.00%)
After-Hours: 18:10
Atrium Therapeutics Gross Profit Margin (Quarterly) : 88.58% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 88.58% |
| March 31, 2026 | 99.23% |
| December 31, 2025 | 85.80% |
| Date | Value |
|---|---|
| June 30, 2025 | 97.95% |
| March 31, 2025 | 96.63% |
| December 31, 2024 | 98.05% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Tenax Therapeutics, Inc. | -- |
| Exicure, Inc. | -- |
| Century Therapeutics, Inc. | -- |
| Absci Corp. | -747.8% |
| Celularity, Inc. | -123.6% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -61.28% |
| Return on Assets | -40.65% |
| Return on Invested Capital | -60.03% |
| Profit Margin (Quarterly) | -672.0% |
| Operating Margin (Quarterly) | -752.9% |
| Return on Net Operating Assets | -578.8% |